Daniel, a man in his seventies from the United States, had advanced non-small cell lung cancer. He also had Parkinson’s disease, which the team in Shanghai would later manage alongside his cancer treatment.
Daniel had received several lines of treatment at MD Anderson Cancer Center. His cancer continued to progress through third- and fourth-line treatment. In November 2025, his doctor brought up ivonescimab, an antibody that targets PD-1 and VEGF. China had approved it for a specific group of lung cancer patients in 2024, and the drug was not commercially available in the United States when his family was looking for options.
Daniel’s children, both physicians, contacted several providers before choosing Jiahui International Cancer Center. According to the hospital, the family had a video consultation in late November with an oncology team that included a clinical pharmacist. They decided to travel to Shanghai after discussing his care with the team.
Daniel received ivonescimab at Jiahui International Hospital. During treatment, the hospital reported immune-related side effects that required intensive care. He returned to a general ward as his condition stabilized. On March 5, 2026, Jiahui reported that Daniel’s lung cancer was stable after about two months of treatment. By March 14, he had been discharged and was receiving follow-up care, according to Shangguan News.
Sources
China Care did not provide the care described. This story does not imply a relationship with the patient or hospital, or that China Care can arrange the same treatment. Individual outcomes do not predict other patients’ results. This is editorial information, not medical advice.